PriceTargets.com logo

Dynavax Technologies - DVAX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 123.02%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.21 As of 04/26/2024 01:00 AM ET
▲ +0.04 (0.36%)

This chart shows the closing price for DVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dynavax Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DVAX

Analyst Price Target is $25.00
▲ +123.02% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Dynavax Technologies in the last 3 months. The average price target is $25.00, with a high forecast of $28.00 and a low forecast of $20.00. The average price target represents a 123.02% upside from the last price of $11.21.

This chart shows the closing price for DVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Dynavax Technologies. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2024William BlairReiterated RatingOutperformLow
2/1/2024The Goldman Sachs GroupInitiated CoverageNeutral$20.00Low
11/3/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $27.00Low
11/3/2023HC WainwrightBoost TargetBuy ➝ Buy$27.00 ➝ $28.00N/A
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00Low
8/4/2023JMP SecuritiesBoost TargetOutperform ➝ Outperform$24.00 ➝ $25.00Low
5/3/2023JMP SecuritiesLower Target$25.00 ➝ $24.00Low
2/24/2023JMP SecuritiesBoost TargetMarket Outperform$22.00 ➝ $25.00Low
2/24/2023HC WainwrightLower TargetBuy$28.00 ➝ $27.00Low
11/4/2022The Goldman Sachs GroupLower TargetBuy$24.00 ➝ $21.00Low
9/27/2022JMP SecuritiesInitiated CoverageOutperform$22.00Low
1/12/2022HC WainwrightInitiated CoverageBuy$28.00Medium
12/29/2021HC WainwrightBoost TargetBuy$23.00 ➝ $28.00High
10/1/2021William BlairReiterated RatingHoldLow
9/27/2021The Goldman Sachs GroupReiterated RatingBuyHigh
9/17/2021William BlairReiterated RatingBuyLow
9/15/2021HC WainwrightInitiated CoverageBuy$23.00Medium
8/31/2021HC WainwrightBoost TargetBuy$20.00 ➝ $23.00High
8/6/2021The Goldman Sachs GroupInitiated CoverageBuy$19.00High
8/5/2021HC WainwrightBoost TargetBuy$16.00 ➝ $20.00High
2/1/2021HC WainwrightBoost TargetBuy$14.00 ➝ $15.00Low
12/18/2020William BlairReiterated RatingBuyHigh
12/11/2020HC WainwrightReiterated RatingBuyHigh
11/6/2020HC WainwrightBoost TargetBuy$12.00 ➝ $14.00High
9/10/2020HC WainwrightReiterated RatingBuyLow
8/3/2020HC WainwrightBoost TargetBuy$12.00 ➝ $14.00High
7/21/2020William BlairReiterated RatingBuyLow
7/10/2020William BlairReiterated RatingBuyMedium
6/19/2020CowenReiterated RatingBuy$20.00Low
6/19/2020HC WainwrightReiterated RatingBuy$12.00High
6/15/2020Evercore ISIInitiated CoverageOutperform$14.00Low
3/29/2020HC WainwrightReiterated RatingBuy$12.00High
3/13/2020William BlairReiterated RatingBuyLow
3/12/2020HC WainwrightLower TargetBuy$13.00 ➝ $12.00High
1/3/2020William BlairReiterated RatingBuyMedium
12/6/2019William BlairReiterated RatingBuyLow
11/7/2019HC WainwrightReiterated RatingBuyHigh
10/18/2019HC WainwrightInitiated CoverageBuy$13.00High
8/16/2019William BlairReiterated RatingBuyLow
7/10/2019Cantor FitzgeraldUpgradeNeutral ➝ Overweight$20.00High
6/21/2019William BlairReiterated RatingBuyMedium
6/3/2019CowenReiterated RatingBuyMedium
5/24/2019William BlairReiterated RatingBuyHigh
5/24/2019Royal Bank of CanadaLower TargetOutperform$13.00High
5/9/2019William BlairReiterated RatingOutperformHigh
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/29/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 10 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 7 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 7 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Dynavax Technologies logo
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $11.21
Low: $11.03
High: $11.26

50 Day Range

MA: $12.23
Low: $11.17
High: $13.14

52 Week Range

Now: $11.21
Low: $10.06
High: $15.15

Volume

1,876,112 shs

Average Volume

2,032,941 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Dynavax Technologies?

The following sell-side analysts have issued research reports on Dynavax Technologies in the last twelve months: HC Wainwright, JMP Securities, StockNews.com, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for DVAX.

What is the current price target for Dynavax Technologies?

3 Wall Street analysts have set twelve-month price targets for Dynavax Technologies in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 123.0%. HC Wainwright has the highest price target set, predicting DVAX will reach $28.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $20.00 for Dynavax Technologies in the next year.
View the latest price targets for DVAX.

What is the current consensus analyst rating for Dynavax Technologies?

Dynavax Technologies currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DVAX.

What other companies compete with Dynavax Technologies?

Other companies that are similar to Dynavax Technologies include Ironwood Pharmaceuticals, Ligand Pharmaceuticals, Geron, MannKind and Prothena. Learn More about companies similar to Dynavax Technologies.

How do I contact Dynavax Technologies' investor relations team?

Dynavax Technologies' physical mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company's listed phone number is (510) 848-5100 and its investor relations email address is [email protected]. The official website for Dynavax Technologies is www.dynavax.com. Learn More about contacing Dynavax Technologies investor relations.